Latest news with #CNDR
Entrepreneur
4 days ago
- Business
- Entrepreneur
Profitable, AI-Powered Tech, Now Preparing for a Potential Public Listing
Everyday investors now have their first opportunity to join, with exclusive bonuses available until June 13. Disclosure: Our goal is to feature products and services that we think you'll find interesting and useful. If you purchase them, Entrepreneur may get a small share of the revenue from the sale from our commerce partners. Since 2003, ConsumerDirect has helped consumers take control of their finances, maturing into a massive fintech platform that earned over $100M in gross revenue last year alone1. And it all happened without relying on venture capital or private equity. Now the company is preparing for a potential public listing*, having already reserved the ticker symbol CNDR2. But instead of turning to institutions or private equity to meet listing requirements, they're opening this round to the people who made their success possible: everyday people who are taking control of their financial lives. So it's no wonder investors are learning all they can about what's driving ConsumerDirect's success before the key June 13 deadline3. The technology powering ConsumerDirect's growth At the center of ConsumerDirect's platform is SmartCredit®, a suite of tools that lets consumers track and maximize their credit in real time. And behind SmartCredit® is Max AI™, a proprietary intelligence engine that analyzes up to 9,000 data points4 per user to deliver personalized credit-building strategies. This is what makes the platform different: it's an intelligent system that adapts to each person's unique financial picture. And because MaxAI™ is deeply integrated into the platform, ConsumerDirect monetizes this engine through a diversified model: Direct-to-Consumer Subscriptions – Monthly fees for SmartCredit® access – Monthly fees for SmartCredit® access Affiliate Commissions – Revenue from credit cards, loans, and other partner products – Revenue from credit cards, loans, and other partner products Enterprise Licensing – White-label and API partnerships with businesses This high-margin, recurring revenue model has made ConsumerDirect profitable and scalable – a rare combination in fintech. Traction that deserves credit Since launching SmartCredit®, ConsumerDirect has helped its more than 300,000 monthly active users take control of their credit and financial health. That amounts to roughly $3 billion5 in combined savings through more informed lending decisions and personalized credit strategies. That's produced $102 million1 in revenue and $10 million+ in EBITDA1, but what makes those figures even more impressive is their 88% gross margins1. Of course, just as important is their business-to-business reach. More than 3,800 active partners6 now use ConsumerDirect's platform through white-label or co-branded integrations, providing high-margin, recurring revenue and extending the company's influence far beyond direct-to-consumer sales. This mix of profitability, consumer demand, and B2B adoption positions ConsumerDirect for continued success. Why investors are circling June 13 ConsumerDirect recently reserved the ticker symbol CNDR2 in preparation for a potential direct public listing on a national securities exchange. To list on an exchange, they need at least 200 individual investors who've invested $2,500 or more. Instead of courting institutional investors, they're turning to those who power their mission: everyday people. When you invest before June 133 you can receive up to 14% in bonus shares: $2,500+ = 7% bonus $5,000+ = 9% bonus $10,000+ = 11% bonus +3% more for the first 200 investors ConsumerDirect is profitable, growing, and ready to scale further. Don't miss your chance to invest in a real business with real traction before its potential public listing. Secure your ConsumerDirect shares before June 13 to maximize your stake in their growth. This is a paid advertisement for Consumer Direct's CF offering. Please read the offering circular at 1 The financial information presented herein is derived from audited financial statements for the year ended December 31, 2024. Readers should refer to the full audited financial statements and accompanying notes for a comprehensive understanding. 2 Reserving the ticker symbol is not a guarantee that the company will go public. Listing on a national securities exchange is subject to approvals. 3 See our Form C for important details regarding the investment deadline. 4 This number reflects the maximum potential insights generated per member and may vary by individual usage, data availability, and engagement levels as of April 2025. All data is derived from internal methodologies and is unaudited. This information is provided for illustrative purposes only and is subject to change without notice. 5 Calculation Methodology: Our savings calculations are estimates using historical internal data. It is based on analyzing subscribers credit reports that had an increased credit score, while a current subscriber, for two categories: new auto and new mortgage financings. The calculations assumed precise credit score reporting, a consistent correlation between score ranges and financing rates, uniform loan terms except for interest rates, and steady interest rates over the loan's term, along with unvarying borrowing behaviors among users. It's important to note that our calculation estimates rely on accurate credit reporting, average loan data and current interest rates, but may not account for an individual subscriber's interest rate variations, if any, or significant shifts in users' borrowing and repayment habits, if any. Additionally, there was an assumed conversion from VantageScore® v3.0 to FICO® v8.0 and then verified by an official FICO® v8.0 calculator to determine savings from starting credit score to credit score before the above mentioned financing occurred. Our calculation is subject to change without notice. 6 Based on internal company records as of March 2025. It reflects partners who engaged in qualifying business activities during the specified reporting period, as determined by internal criteria. This information is provided for informational purposes only and does not represent a guarantee of current or future partner activity. The definition of "active" may vary, and the active partners count is subject to change without notice.
Cision Canada
27-05-2025
- Health
- Cision Canada
Brain Canada Invests in Expansion of National Neuromuscular Disease Registry to Advance Patient-Centered Research Français
CALGARY, AB, May 27, 2025 /CNW/ - Brain Canada is investing in transformative research platforms across the country to accelerate neuroscience discovery and improve outcomes for people living with brain-related conditions. As part of this national initiative, Dr. Lawrence Korngut at the University of Calgary has been awarded a 2024 Platform Support Grant (PSG) of $553,660 to expand the Canadian Neuromuscular Disease Registry (CNDR) into a multi-modal, open science platform. "By expanding the CNDR, we're deepening our understanding of the lived experience of people with neuromuscular disorders. This evolution not only supports the development of better treatments but also ensures that patient voices are reflected in the data that drives discovery." — Dr. Lawrence Korngut, University of Calgary "This audacious national effort reflects Brain Canada's commitment to a culture of open science grounded in transparency, collaboration, and increased access to shared resources, services, facilities and more." — Dr. Viviane Poupon, President and CEO of Brain Canada. The Platform Support Grants program is a cornerstone of Brain Canada's strategy to strengthen the country's neuroscience and mental health research infrastructure. By supporting shared platforms, including databases, biobanks, specialized equipment, and research facilities, the program enables collaboration, accelerates discovery, and expands access to cutting-edge tools to Canadian scientists. The ambitious task of studying the brain calls for integrated and collaborative research platforms. By funding these platforms, we are building a foundation that Canadian researchers will use to strengthen the future of all neuroscience and mental health research. Brain Canada is committed to fostering a culture of open science through transparency and collaboration. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. Over the coming weeks, Brain Canada will unveil the full list of 14 research platforms selected to receive PSG funding. The total investment of $36.8 million represents a major step forward in Canada's ability to support cutting-edge brain research and improve outcomes for people living with brain-disorders. The Canadian Neuromuscular Disease Registry (CNDR) supports research and tracks the effectiveness of treatments for neuromuscular disorders (NMDs), which are rare and complex conditions that affect nerves and muscles. By collecting data from over 40 clinics with more that 5,800 patients across Canada and collaborating with over 130 researchers, the CNDR has become an extensive network for standardized data collection and a valuable resource for advancing research in NMDs. Integrating patient-reported outcome measures into its various registries, including a new one for fascioscapulohumeral muscular dystrophy (FSHD), to capture severity and quality of life more frequently, will improve our understanding of the lived experience of people with NMDs and add depth to CNDR data across all diseases.
Yahoo
27-05-2025
- Business
- Yahoo
Brain Canada Invests in Expansion of National Neuromuscular Disease Registry to Advance Patient-Centered Research
CALGARY, AB, May 27, 2025 /CNW/ - Brain Canada is investing in transformative research platforms across the country to accelerate neuroscience discovery and improve outcomes for people living with brain-related conditions. As part of this national initiative, Dr. Lawrence Korngut at the University of Calgary has been awarded a 2024 Platform Support Grant (PSG) of $553,660 to expand the Canadian Neuromuscular Disease Registry (CNDR) into a multi-modal, open science platform. "By expanding the CNDR, we're deepening our understanding of the lived experience of people with neuromuscular disorders. This evolution not only supports the development of better treatments but also ensures that patient voices are reflected in the data that drives discovery." — Dr. Lawrence Korngut, University of Calgary "This audacious national effort reflects Brain Canada's commitment to a culture of open science grounded in transparency, collaboration, and increased access to shared resources, services, facilities and more." — Dr. Viviane Poupon, President and CEO of Brain Canada. The Platform Support Grants program is a cornerstone of Brain Canada's strategy to strengthen the country's neuroscience and mental health research infrastructure. By supporting shared platforms, including databases, biobanks, specialized equipment, and research facilities, the program enables collaboration, accelerates discovery, and expands access to cutting-edge tools to Canadian scientists. The ambitious task of studying the brain calls for integrated and collaborative research platforms. By funding these platforms, we are building a foundation that Canadian researchers will use to strengthen the future of all neuroscience and mental health research. Brain Canada is committed to fostering a culture of open science through transparency and collaboration. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. Over the coming weeks, Brain Canada will unveil the full list of 14 research platforms selected to receive PSG funding. The total investment of $36.8 million represents a major step forward in Canada's ability to support cutting-edge brain research and improve outcomes for people living with brain-disorders. About The Platform: Expanding CNDR as an Open Science, Multi-modal Data Platform: Dr. Lawrence Korngut, University of Calgary Total grant amount: $553,660.00 The Canadian Neuromuscular Disease Registry (CNDR) supports research and tracks the effectiveness of treatments for neuromuscular disorders (NMDs), which are rare and complex conditions that affect nerves and muscles. By collecting data from over 40 clinics with more that 5,800 patients across Canada and collaborating with over 130 researchers, the CNDR has become an extensive network for standardized data collection and a valuable resource for advancing research in NMDs. Integrating patient-reported outcome measures into its various registries, including a new one for fascioscapulohumeral muscular dystrophy (FSHD), to capture severity and quality of life more frequently, will improve our understanding of the lived experience of people with NMDs and add depth to CNDR data across all diseases. SOURCE Brain Canada View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Brain Canada Invests in Expansion of National Neuromuscular Disease Registry to Advance Patient-Centered Research
CALGARY, AB, May 27, 2025 /CNW/ - Brain Canada is investing in transformative research platforms across the country to accelerate neuroscience discovery and improve outcomes for people living with brain-related conditions. As part of this national initiative, Dr. Lawrence Korngut at the University of Calgary has been awarded a 2024 Platform Support Grant (PSG) of $553,660 to expand the Canadian Neuromuscular Disease Registry (CNDR) into a multi-modal, open science platform. "By expanding the CNDR, we're deepening our understanding of the lived experience of people with neuromuscular disorders. This evolution not only supports the development of better treatments but also ensures that patient voices are reflected in the data that drives discovery." — Dr. Lawrence Korngut, University of Calgary "This audacious national effort reflects Brain Canada's commitment to a culture of open science grounded in transparency, collaboration, and increased access to shared resources, services, facilities and more." — Dr. Viviane Poupon, President and CEO of Brain Canada. The Platform Support Grants program is a cornerstone of Brain Canada's strategy to strengthen the country's neuroscience and mental health research infrastructure. By supporting shared platforms, including databases, biobanks, specialized equipment, and research facilities, the program enables collaboration, accelerates discovery, and expands access to cutting-edge tools to Canadian scientists. The ambitious task of studying the brain calls for integrated and collaborative research platforms. By funding these platforms, we are building a foundation that Canadian researchers will use to strengthen the future of all neuroscience and mental health research. Brain Canada is committed to fostering a culture of open science through transparency and collaboration. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. Over the coming weeks, Brain Canada will unveil the full list of 14 research platforms selected to receive PSG funding. The total investment of $36.8 million represents a major step forward in Canada's ability to support cutting-edge brain research and improve outcomes for people living with brain-disorders. About The Platform: Expanding CNDR as an Open Science, Multi-modal Data Platform: Dr. Lawrence Korngut, University of Calgary Total grant amount: $553,660.00 The Canadian Neuromuscular Disease Registry (CNDR) supports research and tracks the effectiveness of treatments for neuromuscular disorders (NMDs), which are rare and complex conditions that affect nerves and muscles. By collecting data from over 40 clinics with more that 5,800 patients across Canada and collaborating with over 130 researchers, the CNDR has become an extensive network for standardized data collection and a valuable resource for advancing research in NMDs. Integrating patient-reported outcome measures into its various registries, including a new one for fascioscapulohumeral muscular dystrophy (FSHD), to capture severity and quality of life more frequently, will improve our understanding of the lived experience of people with NMDs and add depth to CNDR data across all diseases. SOURCE Brain Canada View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Irish Independent
22-05-2025
- Business
- Irish Independent
Approval for new car-park at Apple's Cork campus has 22 conditions
The council has attached 22 conditions to the planning permission to Apple Operations International Ltd (AOIL) for the additional spaces on land banks it owns to the north of David McCarthy Rd on the north side of the city. The permission follows consultants for Apple, DBFL Consulting Engineers, telling the council that the number of employees is expected to reach 5,350 across the entire Hollyhill campus by mid-2025. DBFL state there is a longer-term projection 'of 6,000 employees by 2030 subject to market conditions'. The permission for the 285 spaces is in addition to the 2,572 parking spaces either on-site or under construction at the Hollyhill campus. In a planning report lodged with the application, consultants HW Planning stated that the proposal is appropriate to facilitate the continued successful operation of Apple operations in Cork and to meet the growing needs of their operations across Ireland and Europe 'in the absence of frequent public transport provision'. They state that the additional car spaces are required for the continued success of this strategic employment hub despite initiatives being implemented to promote sustainable travel options. In the longer term, there may be scope to repurpose these spaces to higher-value uses that support the expansion of the Apple campus Outlining the background to the application, DBFL state that 'the additional spaces are requested to provide short-medium term resilience and mitigate anticipated delays to the planned public transport and road network improvements ahead of the opening of the Hollyhill 5 building in mid-2025'. 'In the longer term, there may be scope to repurpose these spaces to higher-value uses that support the expansion of the Apple campus – once the planned key upgrades to Cork's transport network are delivered,' the report states. Initially, the Cork Metropolitan Area Transport Strategy (CMATS) 2040 envisaged the construction of the Cork Northern Distributor Multi-Modal Road (CNDR) by 2027 which would provide orbital active travel and public transport connectivity to the campus. 'However, the likelihood is that the delays to the roll-out of the CNDR, will necessitate short-medium term requirement of the proposed car-parking,' the report states.
